A St. Jude Children’s Research Hospital team reported in Science that tumors can disable dendritic cells by reprogramming mitochondrial metabolism, weakening the cells’ ability to initiate antitumor immune responses. The study identifies mitochondrial fitness in dendritic cells as a mechanistic gate for effective immune activation in tumor-bearing models. In preclinical mouse experiments, boosting mitochondrial function in dendritic cells restored immunogenic activity and improved tumor control. The researchers further reported synergy when the mitochondrial-enhanced dendritic cells were combined with immune checkpoint blockade, producing a more pronounced survival benefit than either strategy alone. The work frames the tumor microenvironment as a nutrient-sparse setting that gradually reduces dendritic mitochondrial activity, contributing to immune dysfunction. It also describes a longer-term re-challenge design after treatment to assess durability. For immunotherapy teams, the immediate translational implication is that mitochondrial-support approaches in antigen-presenting cells may complement existing checkpoint therapies rather than replacing them.